-Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue-Innovative breast implant technology designed to address a $3.0 billion market opportunity-Cash and cash equivalents balance as of September 30, 2024 was $15.4 million-Conference call to be held today at 10:00 a.m. U.S. EDT –REHOVOT, Israel, Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotech ...